Skip to content

Google

Isomorphic Labs raises $5B to design medicines with AI

2 min read

Written by an AI model from the linked sources and checked against them by a second model. How we work

Image: threads.com

Isomorphic Labs, the drug-discovery company founded by Demis Hassabis, has raised $5 billion in a Series C co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz and several other new investors joining, Isomorphic Labs said on November 17. The money goes into scaling IsoDDE, its in-house AI drug design engine, and its pipeline of AI-designed drug candidates, none of which has been tested in people yet: the company expects its first human trials to start by the end of 2026.

Alphabet, where Isomorphic was set up as a spin-off from DeepMind in 2021, is continuing what the company calls significant investment. Every existing investor came back too: Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund.

The round comes six months after a $2.1 billion Series B on May 12, again led by Thrive Capital. The Pharma Letter called that round the largest financing in AI-driven drug discovery to date and put Isomorphic’s outside capital at roughly $2.7 billion across its first two rounds, the earlier one being $600 million. So this one round is already nearly twice what outside investors had put in before it.

IsoDDE is software that predicts how a drug molecule will fit onto its target, not a drug itself. In a technical report published on February 10, the company said it more than doubles AlphaFold 3’s accuracy on the hardest protein-ligand systems in the Runs N’ Poses benchmark, the cases where a small drug-like molecule has to fit onto a protein, and does 2.3 times better than AlphaFold 3 at high-fidelity prediction of how antibodies bind their targets. Those are the company’s own benchmark results and have not been independently replicated, The Pharma Letter notes.

Isomorphic also earns money from partners. Its deals with Eli Lilly and Novartis, announced in January 2024, include upfront and milestone payments and, per the company, “have the potential to be worth nearly $3 billion to Isomorphic Labs,” not counting potential royalties on future drug sales.

Its own medicines are further back. Several lead candidates are in IND-enabling studies, the lab and animal work US regulators require before a first human trial, and the company expects to file its first IND application and begin first-in-human testing by the end of 2026. As of early November, president Max Jaderberg said the programs were still preclinical, and no first human study had been announced.

No comments yet. Be the first.

Join the conversation

Sign in to leave a comment. It appears after moderation.